Systematic review: Macrophage activation syndrome in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 11, 2013, Pages 1033-1045

  Fries, W ^a   Cottone, M ^b   Cascio, A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; VALGANCICLOVIR; VINCRISTINE;

ANTIBIOTIC THERAPY; BIOLOGICAL THERAPY; BLOOD TRANSFUSION; CLINICAL FEATURE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DISEASE ASSOCIATION; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; FEVER; GENETIC SUSCEPTIBILITY; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE ACTIVATION SYNDROME; MOLECULAR DIAGNOSIS; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; OPPORTUNISTIC INFECTION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SPLENECTOMY; SPLENOMEGALY; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MACROPHAGE ACTIVATION SYNDROME; RISK FACTORS;

EID: 84877591869     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12305     Document Type: Review

References (91)

1. Henter JI, Horne A, Aricò M, et al,. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-31.
2. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al,. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-9.
3. Feldmann J, Callebaut I, Raposo G, et al,. MUNC13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115: 461-73.
4. Tang YM, Xu XJ,. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment. ScientificWorldJournal 2011; 11: 697-708.
5. Menasche G, Pastural E, Feldmann J, et al,. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25: 173-6.
6. Kaplan J, De Domenico I, Ward DM,. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15: 22-9.
7. Enders A, Zieger B, Schwarz K, et al,. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108: 81-7.
8. Engel P, Eck MJ, Terhorst C,. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003; 3: 813-21.
9. Rigaud S, Fondaneche MC, Lambert N, et al,. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444: 110-4.
10. Stephan JL, Kone-Paut I, Galanbrun C, Mouy R, Bader-Meunier B, Prieur AM,. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285-92.
11. Vastert SJ, van Wijk R, D'Urbano LE, et al,. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49: 441-9.
12. Yanagimachi M, Goto H, Miyamae T, et al,. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J Clin Immunol 2011; 31: 946-51.
13. Sherry B,. Rotavirus and reovirus modulation of the interferon response. J Interferon Cytokine Res 2009; 29: 559-67.
14. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A,. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-6.
15. Ravelli A, Grom AA, Behrens EM, Cron RQ,. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13: 289-98.
16. Reiner AP, Spivak JL,. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67: 369-88.
17. Posthuma EF, Westendorp RG, van der Sluys Veer A, et al,. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn-s disease with azathioprine. Gut 1995; 36: 311-3.
18. Sijpkens YW, Allaart CF, Thompson J, et al,. Fever and progressive pancytopenia in a 20-year-old woman with Crohn-s disease. Ann Hematol 1996; 72: 286.
19. Kanaji S, Okuma K, Tokumitsu Y, Yoshizawa S, Nakamura M, Niho Y,. Hemophagocytic syndrome asociated with fulminant ulcerative colitis and presumed acute pancreatitis. Am J Gastroenterol 1998; 93: 1956-9.
20. Babu TG, Boctor D, Davey A, Bond MC, Jacobson K,. Cytomegalovirus- associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J Pediatr Gastroenterol Nutr 2004; 39: 418-21.
21. Koketsu S, Watanabe T, Hori N, Umetani N, Takazawa Y, Nagawa H,. Hemophagocytic syndrome caused by fulminant ulcerative colitis and cytomegalovirus infection: report of a case. Dis Colon Rectum 2004; 47: 1250-3.
22. Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B,. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse Med 2005; 34: 583-4.
23. Hindupur S,. Hemophagocytosis in hemophagocytic lymphohistiocytosis. Am J Hematol 2005; 80: 299-300.
24. Kohara MM, Blum RN,. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2006; 42: 733-4.
25. James DG, Stone CD, Wang HL, Stenson WF,. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 573-80.
26. Siegel CA, Bensen SP, Ely P,. Should rare complications of treatment influence decision-making in ulcerative colitis? Inflamm Bowel Dis 2007; 13: 242.
27. Francolla KA, Altman A, Sylvester FA,. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Ped Gastroenterol Nutr. 2008; 47: 193-5.
28. Serrate C, Silva-Moreno M, Dartigues P, et al,. Epstein-barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis 2009; 15: 1449-51.
29. Miquel T, Bonnet DP, Leport J, Longuet P, Bletry O, Leport C,. Hemophagocytic syndrome in the course of Crohn's disease: possible association with cytomegalovirus infection. Am J Gastroenterol 2009; 104: 252.
30. Dapena Díaz JL, Díaz de Heredia Rubio C, Bastida Vila P, et al,. Haemophagocytic syndrome: a common pathogenic mechanism of various aetiologies. An Pediatr (Barc) 2009; 71: 110-6.
31. N'guyen Y, Andreoletti L, Patey M, et al,. Fatal epstein-barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease. J Clin Microbiol 2009; 47: 1252-4.
32. Wolschke Ch, Fiedler W, Habermann RC, et al,. 28-year old female patient with respiratory insufficiency, elevated liver enzymes, pancytopenia and fever. Internist (Berl) 2010; 51: 1434-8.
33. Numakura T, Matsuura Y, Takiguchi H, Hara Y, Ameku K, Takashi H,. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi 2010; 48: 449-53.
34. Fox CP, Shannon-Lowe C, Gothard P, et al,. Epstein-barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 2010; 51: 66-9.
35. Uslu N, Demir H, Balta G, et al,. Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever. J Crohns Colitis 2010; 4: 341-4.
36. Deneau M, Wallentine J, Guthery S, et al,. Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. Pediatrics 2010; 126: e977-81.
37. Petrache A, Møller MB, Frederiksen H,. Hemophagocytosis associated with cytomegalovirus infection and azathioprine treatment for inflammatory bowel disease. Ugeskr Laeger 2010; 172: 52-3.
38. Kim YC, Kim GM, Lee HS, et al,. A case of hemophagocytic syndrome in an ulcerative colitis patient. Korean J Gastroenterol 2010; 56: 45-8.
39. Ross S, Rajwal SK, Sugarman I, et al,. Epstein-barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr 2010; 51: 229-31.
40. Gunson RN, Hague R, Gartner B, Aitken C,. A case of a girl presenting with fever, cytopenia, liver dysfunction, hepatosplenomegaly, and hemophagocytosis in the bone marrow. J Clin Virol 2011; 51: 1-3.
41. Côté-Daigneault J, Bernard EJ,. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: a case report and literature review. Can J Gastroenterol 2011; 25: 417-8.
42. Lo Presti MA, Costantino G, Della Torre A, Belvedere A, Cascio A, Fries W,. Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn's colitis: harmful cure? Inflamm Bowel Dis 2011; 17: e145-6.
43. Salado CT, Gallego AG, Carnerero EL, et al,. Hemophagocytic lymphohistiocytosis in Crohn's disease associated with primary infection by Epstein-Barr virus. Inflamm Bowel Dis 2011; 17: e143-4.
44. Biank VF, Sheth MK, Talano J, et al,. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011; 159: 808-12.
45. van Langenberg DR, Morrison G, Foley A, Buttigieg RJ, Gibson PR,. Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: 'A cocktail best avoided, not stirred'. J Crohns Colitis 2011; 5: e469-72.
46. Duque G, Ferreira R, Figueiredo P, et al,. Rare cause of fever in a patient with ulcerative colitis. Inflamm Bowel Dis 2011; 17: e64-5.
47. Ingvardsen JC, Ballegaard VC, Homøe P,. Fatal haemophagocytic lymphohistiocytosis and mononucleosis in a patient with colitis ulcerosa. Ugeskr Laeger 2012; 174: 1461-2.
48. Munoz J, Shareef N, Donthireddy V,. Cytomegalovirus-induced haemophagocytic lymphohistiocytosis syndrome. BMJ Case Rep 2012; doi: 10.1136/bcr.10.2011.4963 [Epub ahead of print].
49. Altaf S, Atreaga GM, Joshi AY, Rodriguez V,. Diffuse large B-cell lymphoma in an adolescent female presenting with Epstein-Barr virus-driven hemophagocytic lymphohistiocytosis: a case report. J Med Case Rep 2012; 6: 141.
50. Fitzgerald MP, Armstrong L, Hague R, Russell RK,. A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's disease patient on azathioprine, successfully treated with rituximab. J Crohns Colitis 2013; 7: 314-7.
51. Weinkove R, Dickson M, Eliadou E, Stace NH, Goossens L, Ferguson P,. Fever and pancytopenia in a patient with Crohn's disease. Gut 2012; doi: 10.1136/gutjnl-2012-303632 [Epub ahead of print].
52. Sun XH, Zheng WJ, Zhang W, Zhao Y,. A clinical analysis of hemophagocytic syndrome in autoimmune diseases. Zhonghua Nei Ke Za Zhi 2010; 49: 836-40.
53. Garrido-Serano A, Pérez Martìn F, Guerrero Igea FJ, Galbarro Muñoz J, Palomo Gil S,. Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease. Gastroenterol Hepatol 2000; 23: 7-8.
54. Weinberg I, Neuman T, Margalit M, Ayman F, Wolf DG, Ben-Yehuda A,. Epstein-barr virus-related diarrhea or exacerbation of inflammatory bowel disease: diagnostic dilemma. J Clin Microbiol 2009; 47: 1588-90.
55. Moltó A, Mateo L, Lloveras N, Olivé A, Minguez S,. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 2010; 77: 271-3.
56. Tiede I, Fritz G, Strand S, et al,. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 + T lymphocytes. J Clin Invest 2003; 111: 1133-45.
57. Toruner M, Loftus EV Jr, Harmsen WS, et al,. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
58. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR,. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005; 141: 165-73.
59. Vacher-Coponat H, Brunet C, Moal V, et al,. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. Transplantation 2006; 82: 558-66.
60. Behrens EM, Canna SW, Slade K, et al,. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011; 121: 2264-77.
61. Parodi A, Davì S, Pringe AB, et al,. Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60: 3388-99.
62. Avalos AM, Busconi L, Marshak-Rothstein A,. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2009; 43: 76-83.
63. Behrens EM, Beukelman T, Paessler M, Cron RQ,. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-8.
64. Fall N, Barnes M, Thornton S, et al,. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56: 3793-804.
65. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L,. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009 May 15; 29 (10): 1106-13.
66. Beaugerie L, Brousse N, Bouvier AM, et al,. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
67. Hahn G, Jores R, Mocarski ES,. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998; 95: 3937-42.
68. de Jong MD, Boucher CA, Danner SA, et al,. Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Res 1998; 37: 1-16.
69. Staras SA, Flanders WD, Dollard SC, Pass RF, McGowan JE Jr, Cannon MJ,. Cytomegalovirus seroprevalence and childhood sources of infection: a population-based study among pre-adolescents in the United States. J Clin Virol 2008; 43: 266-71.
70. Cohen JI,. Epstein-barr virus infection. N Engl J Med 2000; 343: 481-92.
71. Fatahzadeh M, Schwartz RA,. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 2007; 57: 737-63.
72. Arvin A, Gershon A, Seward J, Galil K, Wharton M,. Epidemiology of varicella. In:, Mandell- GL, Bennett GE, Dolin R, eds. Principles and Practice of Infectious diseases. Varicella-Zoster Virus. Cambridge University Press, 2000; 187-205.
73. Rahier JF, Ben-Horin S, Chowers Y, et al,. on behalf of the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
74. Wong GH, Goeddel DV,. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986; 323: 819-22.
75. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ,. BIOBADASER Study Group. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc) 2011; 137: 533-40.
76. Lawrance IC, Radford-Smith GL, Bampton PA, et al,. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor- alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010; 25: 1732-8.
77. Lavagna A, Bergallo M, Daperno M, et al,. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13: 896-902.
78. Torre-Cisneros J, Del Castillo M, Castón JJ, Castro MC, Pérez V, Collantes E,. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1132-5.
79. Davignon JL, Boyer JF, Jamard B, Nigon D, Constantin A, Cantagrel A,. Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments. Arthritis Res Ther 2010; 12: R142.
80. Cascio A, Iaria C, Ruggeri P, Fries W,. Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review. Int J Infect Dis 2012; 16: e474-9.
81. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S,. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
82. McKeown E, Pope JE, Leaf S,. Epstein-barr virus (EBV) prevalence and the risk of reactivation in patients with inflammatory arthritis using anti-TNF agents and in those who are biologic naive. Open Rheumatol J 2009; 3: 30-4.
83. Kotlyar DS, Osterman MT, Diamond RH, et al,. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
84. Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M,. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 51: 402-4.
85. Freeman HR, Ramanan AV,. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child 2011; 96: 688-93.
86. Janka GE,. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007; 166: 95-109.
87. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL,. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011; 56: 154-5.
88. Witkowska AM,. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005; 3: 121-30.
89. Russell SE, Moore AC, Fallon PG, Walsh PT,. Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. PLoS ONE 2012; 7: e47748.
90. Bleesing J, Prada A, Siegel DM, et al,. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 965-71.
91. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL,. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118: 4041-52.